drugset / Trial / NCT04979923

Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial

NCT04979923

Phase 1 Unknown 81 enrolled Sheikh Zayed Medical College
RandomizedParallel-groupDouble-blindSupportive care

Summary

The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.

Timeline

Start
2021-07-01
Primary completion
2021-07-31
Completion
2021-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified Inhaled